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A nticoagulants, although effective in the treatment of venous thrombotic dis- 
ease, have not been generally helpful in 
preventing arterial thrombosis. The reason 
for this disparity may lie in the type of clot 
formed in each case. In veins a “red throm- 
bus” is formed, consisting of erythrocytes, 
leukocytes, fibrin, and platelets randomly 
distributed, whereas in arteries a “white 
thrombus” consisting mainly of platelets 
and fibrin strands is the obstructing lesion.’ 
The predominance of platelets in this 
“white” clot has focused attention on their 
importance in arterial occlusion and has 
suggested that therapeutic maneuvers di- 
rected at platelet function may be more 
useful than standard anticoagulant ther- 
apy. This review presents the recent ad- 
vances in the study of platelet morphology 
and function, and concludes by discussing 
possible therapeutic avenues. 
Platelet morphology 
Platelet morphology, as viewed through 
the electron microscope, has advanced the 
understanding of function (Fig. 1). This 
cross-sectional view of a normal human 
platelet shows several important struc- 
tures, all of which will be discussed in 
greater detail later. The trilaminar mem- 
brane is covered with an amorphous “sur- 
face coat” which may be of great im- 
portance in platelet adhesion. The cell 
maintains, in vivo, a lenslike shape, prob- 
ably because of a submembranous “skele- 
ton,” the microtubules. Cytoplasmic, or 
submembranous, microfibrils are sometimes 
seen and may participate in clot retraction. 
The interior of this non-nucleated cell con- 
sists of (a) mitochondria, permitting respi- 
ration and ATP production, (b) the alpha 
granules, which contain fibrinogen, fibrin- 
stabilizing factor (otherwise known as 
platelet factor 4), nonmetabolic ADP and 
ATP, and a number of enzymes,2 and (c) 
the dense bodies, probably derived directly 
from the alpha granules,3 which contain 
stored serotonin, epinephrine, and norepi- 
nephrine. A canalicular system represent- 
ing tubelike invaginations of the cell mem- 
brane into the cytoplasm is sometimes 
visible. 
Platelet aggregation and hemostasis 
The first event in formation of a platelet 
thrombus, in vivo, takes place at the site 
of vessel injury when platelets begin to ad- 
here to the damaged vessel wall and to each 
other.4 Why the individual, circulating non- 
sticky platelet should suddenly become a 
communal, sessile, sticky cell is not fully 
understood. The intact endothelium of un- 
damaged vessels appears to serve as a 
barrier that prevents platelet contact with 
activators in the subendothelial tissues. If 
endothelial disruption occurs, platelets be- 
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Fig. 1. A cross-sectional view of two normal human platelets. Note the biconvex shape best seen in the up )per 
platt :let. SC: Surface coat and trilaminar membrane. mi: Mitochondria. dg: Dense granule. c: Canalicl ular 
system. nzt: Microtubules. g: Glycogen granules. 
gin to adhere to the injured area.5 This may 
be due to exposure of collagen fibrils which 
are potent inducers of this phenomenon,6 to 
the elaboration of ADP in endothelial cyto- 
plasm, which if released by injury, might 
also activate platelets,’ or to possible 
changes in the electrical surface potential 
of normal endothelium which repels plate- 
lets.8 This adhesiveness cannot be pre- 
vented by l~eparinization.g 
In these circumstances, platelets not only 
stick to injured vessel walls but also to 
each other. The growing platelet mass ini- 
tiates hemostasis by mechanically plugging 
the gap in the vessel wall. This attraction 
of one platelet to another, called aggrega- 
tion, is another poorly understood phenom- 
enon. Probably of great importance here, 
though, is the surface coating of the plate- 
let membrane. This material is of irregular 
thickness, and consists of sulfated acid 
mucopolysaccharides. lo It is part of the 
platelet membrane, not just absorbed ma- 
terial, and it is present between the demar- 
cating membranes of developing platelets 
in the megakaryocyte.” Plasma constitu- 
ents, including fibrinogen, are adsorbed to 
this material. Indeed, fibrinogen, whether 
of plasma or platelet origin, calcium, and 
other plasma cofactors that are less well 
defined seem to be necessary for aggrega- 
tion in vitro.12-14 Conversely, fibrinogen 
breakdown products inhibit platelet aggre- 
gation.15 Within grossly normal limits, how- 
ever, fibrinogen levels in vivo do not corre- 
late with speed or completeness of platelet 
aggregation.16 
Aggregation, per se, does not result in 
platelet destruction or irreversible change 
in these cells (Fig. 2). Membranes remain 
intact, and a gap of 200 to 300 A separates 
the aggregated cells. This gap is bridged 
by radially aligned fibrillary material (Fig. 
3), the exact nature and significance of 
which are uncertain.‘? Regardless of the 
inciting event, platelet aggregation seems 
to be mediated by adenosine diphosphate 
(ADP).18 Collagen, epinephrine, and throm- 
bin are three potent aggregating agents, 
but each acts by causing platelets to release 
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Fig. 2. Human platelet aggregate. The microtubules (mt) have been sectioned longitudinally. Pseudopod 
form [ation is seen. Note the preservation of cell membrane integrity (arrow). 
endogenous ADP stores, which, in turn, 
promote clumping. Endogenous ADP seems 
to be more potent in this regard than is 
exogenous ADP. l4 This effect of ADP is 
short-lived, and platelets will disaggregate 
even when appreciable amounts of ADP 
remain in the surrounding medium.lg 
Why ADP produces platelet aggregation 
is not well understood. It may alter the 
normally negative surface charge that all 
platelets carry and reduce their propensity 
to repel one another.8~20 Some authors 
theorize that an ATPase, an enzyme which 
normally dephosphorylates ATP to ADP, 
resides in or near the platelet membrane.21,22 
This enzyme may be continually active, 
and through this activity may keep the 
platelet unsticky. ADP, however, may in- 
hibit this ATPase and thereby cause ag- 
gregation. 
Another consideration of importance is 
the presence on the platelet membrane of 
adrenergic receptor sites (Fig. 4). When 
catecholamines incite platelet aggregation, 
their effect is mediated through alpha recep- 
tors and can be inhibited by alpha blockers. 
Beta receptor stimulators, such as iso- 
prenaline, cause disaggregation in vitro.23 
The beta receptor blocker, propranolol, is 
inactive except at high concentration. As 
in other tissues, catecholamines may act by 
influencing adenyl cyclase, the enzyme 
which catalyzes the formation of cyclic 
AMP. Epinephrine has been shown to in- 
hibit the normal synthesis of cyclic AMP 
in intact platelets after prostaglandin E 1 
stimulation. Phentolamine, an alpha antag- 
onist, blocks this action of epinephrine.24 
Moreover, methyl xanthines, such as caf- 
feine, reduce platelet aggregation by inhib- 
iting phosphodiesterase, an enzyme which 
degrades cyclic AMP. In this case, there- 
fore, aggregation may be induced by thos: 
influences which diminish platelet stores 
of cyclic AMP. 
Platelets undergo physical changes in 
aggregation. Probably as an initial phe- 
nomenon representing primary interaction 
between some aggregating agents (ADP, 
collagen fibrils) and platelet membrane, the 
platelet changes its shape from disclike to 
spherical, and small spiny projections ap- 
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Fig. 3. Human platelet aggregate. Modest granular centralization has occurred. Fibrillary material is seen 
(WIOWS) spanning the interplatelet gap between intact cell membranes. 
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Fig. 4. Outline of 3’ 5’ cyclic AMP metabolism in human platelets. Factors promoting increased synthesis or 
reduced destruction of 3’ 5’ cyclic AMP inhibit platelet aggregation. The converse is also true. 
pear on its membrane. In doing this it gains 
up to 30 per cent in volume.21s25 Platelet 
aggregates induced by epinephrine, how- 
ever, consist mostly of discoid forms.26 
As mentioned previously, ADP-induced 
aggregation in itself produces no irreversi- 
ble changes in platelet structure and func- 
tion. In vivo, however, although platelet 
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ADP still appears to be an important 
mediator, other agents produce profound 
effects on the platelet, eventually leading 
to its destruction. Of physiologic impor- 
tance are thrombin, produced by the action 
of multiple coagulation factors on pro- 
thrombin, and collagen, found in subendo- 
thelial tissue. Other inducers of this phe- 
nomenon include trypsin, papain, aggre- 
gated gamma globulin, antigen-antibody 
complexes, latex particles, endotoxin, and 
epinephrine.27 The change in platelets 
which they catalyze is known as thedrelense 
reaction. 
The release reaction 
The importance of the release reaction is 
that it converts the fragile and readily dis- 
sociable platelet aggregate into an irreversi- 
bly bound platelet plug which seals the 
vessel disruption. The platelets undergo 
visible alterations. The membrane becomes 
irregular, pseudopods appear, and these 
interdigitate with those of adjacent plate- 
lets to produce a network. In addition, the 
internal organization of the platelet changes 
drastically. The inclusions of the platelet 
become centrally located rather than dif- 
fused throughout the cytoplasm.28 This 
granular centralization is an active process, 
probably mediated by the microtubules 
which formerly served as the platelet’s 
“skeleton” and previously were found 
just beneath the membrane, encircling the 
equator of the cell. These now contract, 
perhaps in response to an influx of calcium, 
and appear to sweep the platelet’s granules 
to the center of the now spherical ce11.2pJ0 
The platelet then degranulates, releasing a 
number of substances into the surrounding 
medium. Granules are not extruded whole, 
but probably empty their contents into a 
canalicular system. The reaction begins 
promptly upon exposure to the inducing 
agent, as in the case of thrombin, where 
lag time is less than a second, and proceeds 
to completion within 40 seconds.2 
By no means is release accomplished by 
a nonselective increase in membrane perme- 
ability. Instead, evidence is accumulating 
that platelets selectively and actively “se- 
crete” specific fractions of stored constitu- 
ents and retain other fractions.31J2 A case 
in point is the release of stored adenine 
nucleotides. If platelets are incubated with 
14C-tagged adenine, they synthesize radio- 
active ATP and ADP. If these same plate- 
lets are then challenged with thrombin, 
however, despite the fact that 60 per cent 
of the total adenine nucleotide content 
is released to the surrounding medium, 
virtually no radioactivity is recovered 
there.32J3 This strongly suggests that the 
cell produces and stores a nonexchangeable 
pool of nucleotides for just this purpose. 
A similar mechanism has been found in the 
case of platelet potassium.2 
The substances of importance, in addi- 
tion to ATP and ADP, which are discharged 
during the release reaction include potas- 
sium, serotonin, some enzymes, platelet fac- 
tor 4, proteins, and fibrinogen. These are 
located principally in platelet granules. On 
the other hand, cell constituents found in 
the soluble fraction of cytoplasm, mem- 
branes, or mitochondria are retained dur- 
ing the reaction. These are most of the 
cell’s enzymatic machinery, including such 
lysosomal enzymes as acid phosphatase, 
proteins, lipids, metabolically active ATP 
and ADP, and some of the cell’s fibrino- 
gen.3 
The functions of these released constitu- 
ents have already been alluded to. ADP 
serves to induce aggregation of additional 
platelets to the growing platelet plug, and 
fibrinogen is a necessary cofactor in the 
same process. The role of serotonin is less 
clear, however. This substance may not be 
produced by platelets, but may be ab- 
sorbed from plasma through the platelet’s 
canalicular system, and concentrated and 
stored in dense granules in the cytoplasm 
as a calcium chelate.3,34 Patients with 
carcinoid syndrome show some minor mor- 
phologic abnormalities but have relatively 
normal platelet function.35 Serotonin is a 
weak inducer of aggregation1s18 and, other 
than having vasoconstrictive properties, 
may play no significant role in hemostasis 
or coagulation. Indeed, the platelet may 
serve only as a storage area and transporter 
for this amine. 
PIateIets and the coagulation 
system 
At this point, unless a coagulopathy ex- 
ists, blood-clotting systems are activated. 
Interaction between plasma and platelet 
coagulation factors then becomes impor- 
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tant. A highly simplified version of the cur- 
rently accepted coagulation schema indi- 
cates two points of interaction (Fig. 5). 
Factor X, whether activated by the plasma 
intrinsic system or the tissue extrinsic sys- 
tem, requires the presence of factor V and 
a lipid for conversion to prothrombin acti- 
vator, the substance necessary for forma- 
tion of thrombin.36 In the intrinsic cascade, 
this lipid is platelet factor 3, a lipid or 
lipoprotein complex whose activity seems 
bound to platelet membrane complexes. 
In vitro, such intracytoplasmic complexes 
are seen after the addition of thrombin to 
intact platelets and arise from pre-existing 
alpha granules.37 This factor, which may be 
extruded into the surrounding environment, 
becomes available during the release reac- 
tion. It is also possible that the morphologic 
changes accompanying this event may un- 
mask active surface lipid sites.38 A second 
area of concern is the construction of a tight 
fibrin meshwork after its initial polymeri- 
zation. This is mediated via factor XIII, 
also known as platelet factor 4 or fibrin- 
stabilizing factor. This large protein mole- 
cule is synthesized directly by platelets and 
is secreted into the environment during the 
release reaction.3g,40 It functions by catalyz- 
ing the formation of covalent bonds in the 
fibrin polymer, which serve as cross links to 
reduce the solubility and mechanical fra- 
gility of the new clot. It also inhibits the 
anticlotting properties of fibrin breakdown 
products and interferes with fibrinolysis.41 
A brief mention might be made of an- 
other suspected coagulation function of 
platelets. Some investigators have reported 
the ability of incubated washed platelets to 
clot hemophiliac blood. Since this blood is 
deficient in either factor VIII or factor IX, 
the theory is that these “activated” plate- 
lets have initiated clotting via the extrinsic 
system, and have resembled tissue factor 
in their action.1f42 This presumed function is 
not universally accepted, however, and the 
propensity of platelets to absorb various 
clotting factors to their surfaces hints that 
the missing factors in the intrinsic system 
might have been added this way.38 
Thrombosthenin and clot retraction 
The growing thrombus that we have been 
following now needs only one more bit of 





















Fig. 5. Schematic diagram of the coagulation cas- 
cade. The heavy arrows point to known sites of 
action of platelet factors. 
pleted. This last but very important step 
is known as clot retraction. This reaction 
takes place through the active function of 
the platelet’s contractile protein, throm- 
bosthenin.43 As noted previously, the for- 
mation of pseudopods is a morphologic 
change accompanying the release reaction. 
These projections contain a number of 
microfilaments which lie beneath the cell 
membrane and are dispersed throughout 
the cytoplasm. These microfilaments are 
synthesized in the megakaryocyte, and, 
although they strongly resemble the sub- 
units of human striated or smooth muscle, 
fluorescent antibody studies have not shown 
any cross reactivity.” The contractile sub- 
stance itself appears to be a highly asym- 
metric protein, of high molecular weight, 
which exists in fibrillar form, and which, 
in some studies, appears to have a periodic 
structure like that of actomyosin.30345.47 
Studies of thrombocytes in fishes have 
shown that the protein may be stored in 
vesicles in the resting cell and is po- 
lymerized into fibrillar form only during 
activation.48 Electron micrographs of micro- 
tubules, the submembranous structures dis- 
cussed earlier for their role in preserving cell 
shape, show 13 to 15 subunits, which again 
strongly resemble microfibrils.30 It would 
appear, therefore, that microfibrils and 
microtubules of platelets represent two 
morphologic forms of the same contractile 
protein.4g 
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Light Platelet Photoelectric Recorder 
Source Sample Cell 
Fig. 6. Schematic of device to measure platelet aggregation. 
The stimulus for contraction is unknown, 
but the process appears dependent on ATP 
and calcium. Indeed, thrombosthenin itself 
embodies an ATPase activity which may 
control some of the metabolic steps leading 
to aggregation and release as well as clot 
retraction.22~31*44~66 The contraction, there- 
fore, of thrombosthenin in the pseudopods 
of activated platelets consolidates the clot 
and wrings serum from it, producing a com- 
pleted thrombus. The platelet, its hemo- 
static and coagulation functions completed, 
now dies and is disrupted. It is generally 
removed from the thrombus as healing 
progresses, although platelet antigen is 
present for as long as 6 months in the fibrous 
plaques resulting from experimental mural 
thrombosis in animals.50 
Other platelet functions 
As if all these complex functions of this 
remarkable bit of cytoplasm did not suffice, 
other capabilities have been ascribed to it. 
Platelets seem able to phagocytize virus 
and other particulate material, such as 
Thorotrast.43 Carbon particles injected in- 
travenously into rabbits are probably trans- 
ported to the reticuloendothelial system by 
platelet aggregates. 5l The significance of 
these properties in man’s immunologi- 
cal defenses awaits further study. Further- 
more, platelets aggregate and release when 
incubated with antigen-antibody com- 
plexes, and, in so doing, secrete a factor (or 
factors) which leads (lead) to increased per- 
meability of the vessel walls.5z This may be 
mediated by a cationic protein found in 
extruded platelet granules which stimulates 
mast cells to liberate histamine. The latter, 
in turn, may produce the observed increase 
in vessel permeability.53 The positivity of 
the Rumpel-Leede test in thrombocyto- 
penia may relate to a third ancillary plate- 
let function. If radioactively labeled plate- 
lets are transfused into thrombocytopenic 
guinea pigs, the endothelial cells of the 
blood vessels are seen to bind and incorpo- 
rate platelet cytoplasm into themselves 
rapidly.54,55 This suggests that platelets may 
play a primary metabolic role in the nour- 
ishment and maintenance of intact vascular 
endothelium. 
Tests of platelet function 
One of the principal difficulties in under- 
standing platelet function is that of measur- 
ing it. The platelet count is only a quanti- 
tative measurement, and clot retraction, 
although roughly evaluating thrombosthe- 
nin content, is still dependent on and pro- 
portional to the platelet count.43 Platelet 
factor 3 activity may be estimated by its 
accelerating influence on the clotting effect 
of viper venom, but this study has inade- 
quacies and is not widely available.’ Plate- 
let factor 4 or fibrin-stabilizing-factor ac- 
tivity can be approximated by studies of 
clot solubility in urea and monochloracetic 
acid and of clot elasticity, but again these 
are not widely available.41 Two studies 
which are becoming widely accessible for 
platelet evaluation are the glass-bead- 
column procedure for estimating “adhesive- 
ness” and the photometric measurement of 
platelet aggregation. 
The first study is simple in design. A 
platelet count is done on titrated whole 
blood, which is then passed, at a constant 
velocity, through a known volume of glass 
beads of uniform size. A second platelet 
count is done on the blood emerging from 
the column. The difference between these 
two counts, or that percentage of platelets 
which remains in the column, is taken as a 
measure of platelet “adhesiveness.“56 This 
study is reproducible in experienced 
hands,57 but its clinical usefulness in pre- 
dicting the risk of thrombotic events in 
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Fig. 7. Platelet aggregometer record. Aggregating 
agent used was ADP (added at arrow). 
anticoagulated patients has been ques- 
tioned.68 
The second study is more complex (Fig. 
6). A beam of light of constant intensity is 
focused on a photoelectric cell which con- 
stantly samples the light transmitted and 
records this on a slowly moving papergraph. 
Platelet-rich plasma, which is constantly 
stirred, is placed in this chamber in the 
path of the beam. Baseline transmission of 
light through the platelet mixture is ob- 
tained, and then an aggregating agent of 
choice is added. This induces platelet 
clumping, which tends to clear the solution 
and increase the transmission of light 
through it. A typical record from such a 
study is shown in Fig. 7. The aggregating 
agent used was ADP. Time is noted on the 
abscissa, and increasing transmission of 
light, on the ordinate. After the addition 
of ADP to the system, a brief time lag is 
noted, and then aggregation proceeds. After 
it reaches its maximum, there is a slow 
disaggregation phase represented by this 
slowly decreasing transmission of light. 
Several measurements may be made here, 
including the slope of this line, representing 
the speed of aggregation, the maximum 
amount of aggregation achieved, and the 
time needed for 25 per cent disaggregation. 
1 MIN.-4 
Fig. 8. Platelet aggregometer record. Aggregation 
induced by epinephrine (added at 1). Note two- 
phased response produced by late release of platelet 
ADP stores (2). 
Fig. 8 shows an aggregation curve made 
with the addition of epinephrine. A two- 
phased response is seen, the first phase 
caused by epinephrine’s own effect on 
platelets, and a second more profound rise 
as platelet stores of ADP are released in 
response to the initial stimulus. Retention 
of platelets in the glass-bead column is 
directly proportional to the initial rate of 
platelet aggregation induced by ADP or 
thrombin, thereby relating these two stud- 
ies and suggesting that aggregate forma- 
tion in the column may be the mechanism 
of platelet sequestration there.5g 
Factors modifying platelet function 
Many metabolic situations and thera- 
peutic agents alter these measurements, 
and thereby give some indication of their 
effect on platelet function. For example, 
surgery itself usually produces not only 
an increase in platelet count, but a similar 
rise in the rate and extent of aggregation 
when measured from about the tenth to the 
twentieth postoperative day.6os61 Diabetic 
and normal volunteers rendered hyper- 
glycemic by intravenous infusions of glu- 
cose were found to have increased platelet 
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LLadhesiveness.“62 One group found that the 
feeding of high cholesterol diets to rabljits 
led to beta lipoprotein changes which in- 
creased platelet “adhesiveness” and aggre- 
gation rate,‘j3 but these findings were not 
confirmed by another group which fed an 
atherogenic diet to rabbits.64 In one study, 
patients with recent acute myocardial in- 
farctions, thrombophlebitis, or major arte- 
rial occlusions have demonstrated increased 
platelet “adhesiveness” when compared to 
controls,65 but others have not demon- 
strated increased platelet aggregation in 
the immediate postmyocardial infarction 
period.66 The direct applicability of such 
work to human vascular disease and the 
need for further study are evident. 
In patients with Waldenstrbm’s mac- 
roglobulinemia, platelet aggregates form 
poorly6’ and platelet factor 3 activity de- 
velops subnormally. This may be related 
to effects of the abnormal serum protein on 
platelet membranes, and can be partially 
reversed by incubation of the patient’s 
platelets with antimacroglobulin anti- 
body.68 Although pheochromocytoma is not 
associated with thrombotic complications, 
reduction in platelet “adhesiveness” has 
been demonstrated after removal of the 
tumor.6s 
Drugs also alter platelet function. As 
alluded to previously, phentolamine, an 
alpha receptor blocker, inhibits the aggre- 
gation of platelets by epinephrine.18 Prop- 
ranolol and nitroglycerine inhibit both 
ADP and epinephrine-induced aggregation 
in vitro, but have little effect in vivo.‘O 
Clofibrate, despite some initially promising 
reports, probably does not have an im- 
portant effect on platelet function.‘I Pheno- 
thiazine derivatives seem to interfere with 
release of platelet stores of ADP, perhaps 
through their membrane-stabilizing effects.’ 
Aspirin and, for that matter, sodium salicy- 
late, indomethacin, mefenamic acid, and 
phenylbutazone appear to have a similar 
membrane-stabilizing effect, and prevent 
release of platelet constituents after appro- 
priate induction. 72-74 Aspirin has a particu- 
larly prolonged effect, lasting up to 7 days 
after a single dose, and exerts a particularly 
strong action on preventing the appearance 
of platelet factor 4 activity.75 It may act by 
acetylating active sites on platelet mem- 
branes, and intracytoplasmic constituents.76 
In vitro, heparin in large dosages decreases 
aggregation perhaps because it is a strong 
organic acid. 2o Coumadin, on the other 
hand, actually increased the extent of 
aggregation in anticoagulated patients serv- 
ing as their own controls7’ Colchicine, when 
added to platelet-rich plasma, inhibits 
platelet aggregation, reduces “adhesive- 
ness,” and diminishes clot retraction, the 
latter probably by interference with micro- 
tubular function.78 
Two naturally occurring compounds de- 
serve comment, inasmuch as each is a 
strong inhibitor of platelet aggregation in 
vitro and in vivo. The first is prostaglandin 
E 1, which acts through stimulation of 
adenyl cyclase and increases in platelet 
cyclic AMP stores. 7g-81 The second is 
adenosine, which results from the metabolic 
degradation of ATP and ADP. Its effect, 
however, is transient because of rapid 
deamination in tissues and blood, and its 
hypotensive action is significant.s2 
Dipyridamole, an antiplatelet drug 
The discovery that dipyridamole inhib- 
ited the deamination of adenosine by intact 
human red blood cells suggested the useful- 
ness of this drug as a platelet inhibitor.Y” 
The platelet-inhibiting effects of dipyrida- 
mole became more prominent after publi- 
cation of a well-controlled study, in 1968, 
showing statistically significant reduction 
in arterial embolic events in a treated group 
of patients with prosthetic heart valves.84 
Subsequent enlargement of this study has 
shown increasingly significant protection 
for the dipyridamole-treated patients.Y5 
More recently, platelet survival has been 
found uniformly shortened in anticoagu- 
lated patients with artificial valves, and 
platelet lifespan can be extended to normal 
by adding dipyridamole to the treatment 
program.86 
The direct effects of this drug and its 
analogues on platelet function in vitro are 
a significant decrease in “adhesiveness,” as 
measured by the glass-bead technique, and 
a depression of aggregation, with enhance- 
ment of disaggregation noted in some stud- 
ies.87-8g Another study showed no effect on 
disaggregation, llowever.g0 In vivo animal 
experiments have shown the effectiveness 
of this drug in preventing thrombus forma- 
tion in intentionally damaged arteries.8gzgL 
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Measurable changes in platelets of pa- 
tients taking dipyridamole chronically were 
harder to demonstrate. Although one group 
found a significant decrease in platelet 
“adhesiveness” in 4 of 6 treated patients 
with coronary artery disease,g2 other au- 
thors found no change in similar pa- 
tients 86-88793 
Work from our laboratory also showed 
the difficulty of demonstrating the in vivo 
effect of dipyridamole on platelet function.g4 
Four warfarin-anticoagulated recipients of 
prosthetic heart valves were studied. After 
baseline platelet function* and standard 
coagulation determinationst dipyridamole 
was administered (100 mg. orally four 
times a day) for a period of 7 to 30 days. 
The studies were then repeated, the drug 
was discontinued, and studies were ob- 
tained again 2 to 4 weeks later. The results 
did reveal a significant reduction in clot 
retraction during administration of dipy- 
ridamole, but no other statistically signifi- 
cant difference in platelet function or coag- 
ulation parameters during the control and 
treatment periods. 
Dipyridamole is partially bound to red 
cell membranes, and may thus prevent 
adenosine from diffusing into the cell, where 
it is normally metabolized.82 It also appears 
to inhibit adenosine deaminase, the respon- 
sible enzyme, directly.83 The drug may 
render platelet membranes impermeable to 
adenosine as we11.g5 Although most authori- 
ties believe that the resultant extracellular 
accumulation of adenosine then disturbs 
platelet function, some think that a direct 
effect of dipyridamole on the platelet mem- 
brane may be responsible. 
The purpose of this discussion is to 
emphasize the primary role of platelets in 
the genesis of arterial thrombosis and the 
fact that antiplatelet agents, such as di- 
pyridamole, do exist and may be useful, 
alone or in combination with standard 
anticoagulants, in preventing arterial occlu- 
sion or embolization. The usefuluess of such 
drugs may extend beyond common forms 
of arterial disease. Recent reports of plate- 
let aggregates in renal arterioles and glome- 
ruli of patients with lipoid nephrosis, glo- 
*Studies included ADP, epinephrine. collagen-fibril-induced 
aggregation, and whole blood platelet “adhesiveness.” 
tStudies included platelet count. clot retraction. one-stage 
prothrombin time, partial thromboplastin time. thrombin 
clotting time, and euglobulin lysis. 
merulonephritis, and transplanted kidneys 
undergoing chronic or hyperacute rejection 
reactions point to another possible use of 
these agents. 97-100 Although dipyridamole 
by itself does not prevent severe rejection 
reactions,lol it has been shown, when used 
with Coumadin-like drugs or heparin, or 
both, to give significant protection against 
intrarenal vascular occlusion in such cir- 
cumstances.lo2 Its record of safety and low 
incidence of important side effects should 
make it an attractive antiplatelet agent 
for further study. 
I am indebted to Dr. John Penner and Dr. 
Andrew Zweifler for their encouragement and assist- 
ance in preparing this manuscript, and to Dr. 
Ernest Reynolds, who reviewed it. I also wish to 
thank Dr. Bertram Schnitzer, Department of Path- 
ology, University of Michigan Medical School, who 
so kindly supplied the electron photomicrographs, 
Mrs. Sylvia Romero and Mrs. Janet Layne for 
their technical assistance, and Dr. Leigh S. Whit- 














Marcus, A. J.: Platelet function, New Eng. J. 
Med. 280:1213, 1278, 1330, 1969. 
Holmsen, H., Day, H. J., and Stormorken, H.: 
The blood platelet release reaction, Stand. J. 
Haemat. Suppl. 8, 1969. 
White, J. G. : The dense bodies of human plate- 
lets, Amer. J. Path. 53:791, 1968. 
Mustard, J. F.: Platelets and thrombosis: 
Mechanisms and therapy, Hospital Practice 
4:46, 1969. 
Sherry, Sol, et al., editors: Thrombosis, Wash- 
ington, D. C., 1969, National Academy of 
Sciences. 
Wilner, G. D., Nossel, H. L., and LeRoy, E. C.: 
Aggregation of platelets by collagen, J. Clin. 
Invest. 47:2616, 1968. 
Johnson, S., Webber, A. J., and Chang, C. M.: 
The role of the vessel wall in thrombosis, Blood 
30554, 1967. 
Dawber, J. G., and Roberts, J. C.: An elec- 
trical double layer theory for platelet adhesive- 
ness and initiation of intravascular thrombosis, 
Thromb. Diath. Haemorrh. 19:451, 1968. 
Ashford, T. P., and Freiman, D. G.: Role of 
the endothelium in the initial phases of throm- 
bosis, Amer. 1. Path. 50:257. 1967. 
Shirasawa, I?., and Chandler, A. B.: Fine 
structure of the bond between platelets in 
artificial thrombi and in platelet- aggregates 
induced bv adenosine dinhosohate. Amer. 1. 
Path. 57:127, 1969. - - ” 
Behnke, 0.: Electron microscopical observa- 
tions on the surface coating of human blood 
platelets, J. Ultrastruct. Res. 2451, 1968. 
Deykin, D., Pritzker, C. R., and Scolnik, 
E. M.: Plasma cofactors in adenosine diohos- 
phate induced aggregation of human placelets, 
Nature 208:296, 1965. 
562 Schnetzer Am. Heart J. A#& 1972 
13. Ganguly, P.: Studies on human platelet pro. 
teins. II. Effect of thrombin. Blood 33:590. 
1969. 
14. Haslam, R. J.: Role of adenosiue diphosphate 
in the aggregation of human blood platelets by 










Niewiarowski, S., Ream, V., and Thomas, D.: 
Effect of fibrinogen derivatives on platelet 
aggregation, in Mammen, E., editor: Platelet 
adhesion and aggregation in thrombosis: 
Countermeasures, Stuttgart, 1970, Schattauer, 
p. 49. 
O’Brien, J. R.: Platelet aggregation and plasma 
fibrinogen. Lancet 1:628, 1969. 
Stehbeis,’ W. E., and Biscoe, T. J.: Ultra- 
structure of early platelet aggregation in vivo, 
Amer. I. Path. 50:219. 1967. 
O’BrieG, J. R.: A comparison of platelet aggre- 
gation produced by seven compounds and a 
comparison of their inhibitors, J. Clin. Path. 
17:275, 1964. 
Packham, M. A., Ardlie, N. G., and Mustard, 
J. F. : Effect of adenine compounds on platelet 
aggregation, Amer. J. Physiol. 217:1009, 1969. 
Grijttum, K. A.: Platelet surface charge and 
aggregation. (Effects of polyelectrolytes), 
Thromb. Diath. Haemorrh. 21:450, 1969. 
Salzman, E. W., Ashford, T. P., Chambers, 
D. A.. Neri. I,. L.. and Demoster. A. P.: Plate- 
let volume: Effect of tempe’ratuie and agents 
affecting platelet aggregation, Amer. J. Phy- 
siol. 217:1330, 1969. 
Booyse, F. M., and Rafelson, M. E., Jr.: Studies 
on human platelets. III. A contractile protein 
model for platelet aggregation, Blood 33:100, 
1969. 
23. Abdullah, Y. H.: Beta adrenergic receptors in 
human platelets, 1. Atheroscler. Res. 9:171, 
1969. - - 
24. Marquis, N. R., Becker, J. A.: and Vigdahl, 
R. L.: Platelet aggregation. III. An eoineoh- -- 
rine induced decreaseIn cyclic -4MP synthesis, 




Born, G. V. R.: Quantitative investigations of 
the rapid swelling reaction of blood platelets, 
J. Physiol. (London) 202:93P, 1969. 
iarrimer, N. R., Balcerzak, S. P., Metz, E. N., 
and Lee. R. E.: Surface structure of normal 







Stormorken, H.: The platelet release reaction. 
Its general aspects and relation to phagocyto- 
sis, Stand. J. Clin. Lab. Invest. (Suppl.) 
107:115, 1969. 
White, J. G.: The submembrane filaments of 
blood platelets, Amer. J. Path. 56:267, 1969. 
White, J. G.: The muscular system of platelets, 
Blood 80:539, 1967. 
White, J. G.: The substructure of human plate- 
let microtubules, Blood 32:638, 1968. 
Davev. M. G.. and Liischer. E. F.: Release _ 
reactions of human platelets induced by throm- 
bin and other agents, Biochim. Biophys. Acta 
165:490, 1968. 



















action of release inducers upon platelet release 
and phosphorus metabolism, Biochim. Bio- 
phys. Acta 192:138, 1969. 
Holmsen, H., Day, H. J., and Storm, E.: Ade- 
nine nucleotide metabolism of blood platelets. 
VI. Subcellular localization of nucleotide pools 
with different functions in the platelet release 
reaction, B&him. Biophys. Acta 186:254, 
1969. 
White, J. G.: The dense bodies of human plate- 
lets: Inherent electron opacity of the serotonin 
storage particles, Blood 33:598, 1969. 
White, J. G., and Davis, R. B.: Alterations of 
platelet ultrastructure in patients with carci- 
noid syndrome, Amer. J. Path. 56:519, 1969. 
Deykin, D.: T.hrombogenesis, New Eng. J. 
Med. 276:622, 1967. 
Webber, A. J,, and Johnson, S. A.: Platelet 
participation in blood coagulation aspects of 
hemostasis, Amer. J. Path. 68:19, 1970. 
Castaldi, P. A.: The function of the platelet, 
Bib]. Haemat. 29 (Part 1):98. 1968. 
Lewis, J. H., Bayer, W. i., Wilson, J. H., and 
Szeto, I. L. F.: Factor XIII in platelets, Blood 
30:543, 1967. 
Niewiarowski, S., Lipinski, B., Farbiszewski, 
R., and Poplawski, A.: The release of platelet 
factor 4 during platelet aggregation and possi- 
ble significance of this reaction in hemostasis, 
Experientia 24:343, 1968. 
McDonagh, J., McDonagh, R. P., Jr., Delage, 
J. M., and Wagner, R. H.: Factor XIII in 
human plasma and platelets, J. Clin. Invest. 
48:940, 1969. 
Biggs, R., Denson, K. W. E., Riesenberg, D., 
and McIntyre, C.: The coagulant activity of 
platelets, Brit. J. Haemat. 15:283, 1968. 
Wintrobe, M.: Clinical hematology, Phila- 
delphia, 1967, Lea & Febiger. 
Nachman, R., Marcus, A. J., and Salier, L. B.: 
Platelet thrombosthenin: Subcellular locali- 
zation and function, J. Clin. Invest. 46:1380, 
1967. 
Ganguly, P.: Studies of platelet proteins. IV. 
Some physical and chemical properties of 
thrombosthenin, Blood 34:.511, 1969. 
Zucker-Franklin, D., Nachman, R. L., and 
Marcus, A. J.: Ultrastructure of throm- 
bosthenin, the contractile protein of human 
blood platelets, Science 157:945, 1967. 
Bettex-Galland, M., Mscher, E. F., and 
Weibel, E. R.: Thrombosthenin-Electron 
microscopical studies on its localization in 
human blood platelets and some properties of 
its subunits, Thromb. Diath. Haemorrh. 
22:431, 1969. 
Shepro, D., Belamarich, F. A., Merk, F. B., 
and Chao, F. C.: Changes in thrombocyte 
ultrastructure during clot retraction, J. Cell 
Sci. 4:763, 1969. 
Zucker-Franklin, D.: Microfibrils of blood 
platelets: Their relationship to microtubules 
and the contractile protein, I. Clin. Invest. 
48:165, 1969. _ ” 
Woolf. N.. and Carstairs. K. C.: The survival , 
time of platelets in experimental mural 
thrombi, J. Path. 97:595, 1969. 
Volume 83 
Number 4 Platelets and thrombogenes&---Current concepts 563 
51. Van Aken, W. G., Goote, Th. M., and Vreeken, 
J. : Platelet aggregation: An intermediary 
mechanism in carbon clearance, Stand. J. 
Haemat. 5:333, 1968. 
52. Mustard, J. F., Movat, H. Z., Macmorine, 
D. R. L.. and Senvi. A.: Release of nermeabi!- 
ity factors from the blood platelet, Proc. Sot. 
Exp. Biol. Med. 119:988, 196.5. 
53. Nachman, R. L., Weksler, B., and Ferris, B.: 
Increased vascular permeability produced by 
human platelet granule cationic extract, J. 
Clin. Invest. 49:274, 1970. 
54. Wojcik, J. D., Webber, A. J., and Johnson, 
S. A.: Mechanism whereby platelets strengthen 
and nourish the endothelium, Blood 34:533. 
1969. 
5.5. Wojcik, J. D., Van Horn, D. L., Webber, A. J., 
and Tohnson. S. A.: Mechanism wherebv nlate- 
lets -support the endothelium, Transfusion 
9:324, 1969. 
56. Bowie, E. J. W., Owen, C. A., Thompson, 
J. H., Jr., and Didisheim, P.: A test of platelet 
adhesiveness, Mayo Clin. Proc. 44:306, 1969. 
57. Shaw, S., Pegrum, G. D., and Wolff, S.: Esti- 
mation of platelet adhesiveness on whole blood 












Eastham, R. D.: The irrelevance of adhesive 
olatelet estimation. 1. Clin. Path. 22:742. 
i969. 
”  
Bloom, A. L., and Evans, E. P.: Relationship 
of platelet retention in glass bead columns to 
the rate of aggregation with adenosine diphos- 
phate and thrombin, J. Clin. Path. 22:560, 
1969. 
Emmons, P. R., and Mitchell, J. R. A.: Post- 
operative changes in platelet clumping activ- 
ity, Lancet 1:71, 1965. 
Enticknap, J. B., Lansley, T. S., and Davis, T.: 
Reduction in blood platelet size with increase 
in circulating numbers in the postoperative 
period and a comparison of the glass bead and 
rotating bulb methods for detecting changes 
in function, J. Clin. Path. 23:140, 1970. 
Bridges, J. M., Dalby, A. M., Millar, J. H. D., 
and Weaver, J. A.: An effect of D-glucose on 
platelet stickiness, Lancet 1:75, 1965. 
Farbiszewski, R., and Worowski, K.: The effect 
of modified beta lipoproteins on adhesiveness 
and aggregation of blood platelets, J. Athero- 
scler. Res. 9:339, 1969. 
Kloeze, J., Houtsmuller, U. M. T., and Vles, 
R. D.: Influence of dietary fat mixtures on 
platelet adhesiveness, atherosclerosis, and 
plasma cholesterol content in rabbits, J. 
Atheroscler. Res. 9:319, 1969. 
Bygdeman, S., and Wells, R.: Studies of plate- 
let adhesiveness, blood viscosity, and micro- 
circulation in patients with thrombotic dis- 
ease, J. Atheroscler. Res. 10:33, 1969. 
Enticknap, J. B., Gooding, P. G., Lansley, 
T. S., and Avis, P. R. D.: Platelet size and 
function in ischemic heart disease, J. Athero- 
scler. Res. 10:41, 1969. 
Rosenberg, M. C., and Dintenfass, L.: Platelet 
aggregation in Waldenstrom’s macroglobu- 
linemia, Thromb. Diath. Haemorrh. 14:202, 
1965. 
68. Pachter, M. R., Johnson, S., Neblett, T. R., 
and Truant, J. P.: Bleeding, platelets and 
macroglobulinemia, Amer. J. Clin. Path. 
31:467, 1959. 
69. Danta, G.: Pre- and postoperative platelet 
adhesiveness in pheochromocytoma, Thromb. 
Diath. Haemorrh. 23:189, 1970. 
70. Hampton, J. R., Harrison, M. J. G., Honour, 
A. J., and Mitchell, J. R. A.: Platelet behavior 
and drugs used in cardiovascular disease, 
Cardiovasc. Res. l:lOl, 1967. 
71. O’Brien. I. R.: Platelet function tests and 
clofibrate,*Lancet 2:1143, 1968. 
72. Zucker, M. B., and Peterson, J.: Effect of 
acetylsalicylic acid and other non-steroidal 
anti-inflammatory agents on the release of 
i”C-serotonin from human and rabbit plate- 
lets, Blood 34:536, 1969. 
73. Atac, A., Spagnuolo, M., and Zucker, M. J.: 
L.ong term inhibition of platelet functions by 
aspirin, Proc. Sot. Exp. Biol. Med. 133:1331, 
1970. 
74. Zucker, M. B., and Peterson, J.: Effect of 
acetylsalicylic acid, other non-steroidal anti- 
inflammatory agents and dipyridamole on 
human blood platelets, J. Lab. Clin. Med. 
76:66, 1970. 
75. O’Brien, J. R.: Cell membrane damage, plate- 
let stickiness and some effects of asp&n,- Brit. 
1. Haemat. 17:610. 1969. 
76. Al-Mondhiry, H., ‘Marcus, A. J., and Spaet, 
T. H.: On the mechanism of platelet function 
inhibition by acetylsalicylic acid, Proc. Sot. 
Exp. Biol. Med. 133:632, 1970. 
77. Poller, L., Thompson, J. M., and Priest, C. M.: 
Coumarin therapy and platelet aggregation, 
Brit. Med. J. 1:474, 1969. 
78. Soppitt, G. D., and Mitchell, J. R. A.: The 
effect of colchicine on human platelet behavior, 
J. Atheroscler. Res. 10:247, 1969. 
79. Eckeles, R. S., Hampton, J. R., Harrison, 
M. J. G., and Mitchell, J. R. A.: Prostaglandin 
E 1 and human platelets, Lancet 2:111, 1969. 
80. Marquis, N. R., Vigdahl, R. V., and Tavor- 
mina, P. A.: Platelet aggregation. I. Regula- 
tion by cyclic AMP and prostaglandin E 1, 
Biochem. Biophys. Res. Commun. 86:965, 
1969. 
81. Irion, E., and Blomback, M.: Prostaglandins 
in platelet aggregation, Stand. J. Clin. Lab. 
Invest. 24:141, 1969. 
82. Stafford, A.: Potentiation of adenosine and the 
adenine nucleotides by dipyridamole, Brit. J. 
Pharmacol. 28:218, 1966. 
83. Bunag, R., Douglas, C. R., Imai, S., et al.: 
Influence of a pyrimidopyrimidine derivative 
on deamination of adenosine by blood, Circ. 
Res. 15:83. 1964. 
84. Sullivan, J. Harken, D., and Gorlin, R.: 
Pharmacologic control of thromboembolic 
complications of cardiac valve replacement, 
New Eng. J. Med. 279:576, 1968. 
85. Sullivan, J. M., Harken, D. E., and Gorlin, R.: 
Effect of dipyridamole on the incidence of 
564 Schrtetzer Am. Heart I. April, 1972 
arterial emboli after cardiac valve replace- 
ment. Circulation 39 (.‘%~~1.):149. 1969. 
86. Hark&, L. A.: Platelet kinetics and artificial 
heart valves, Clin. Res. 18:176, 1970. 
87. Gray, G. R., Wilson, P. A., and Douglas, A. S.: 
The effect of dipyridamole on platelet aggre- 
gation and adhesiveness, Scot. Med. J. 13:409, 
1968. 
88. Emmons, P. R., Harrison, M. J., Honour, A. J., 
et al.: Effect of dipyridamole on human plate- 
let behavior, Lancet 2:603, 1965. 
89. Emmons, P. R., Harrison, M. J. G., Honour, 
A. J., and Mitchell, J. R. A.: Effect of pyri- 
midopyrimidine derivative on thrombus for- 
mation in the rabbit, Nature 208:255, 1965. 
90. Eliasson, R., Bygdeman, S.: Effect of dipyrida- 
mole and two pyrimidopyrimidine derivatives 
on the kinetics of human platelet aggregation 
and on platelet adhesiveness, Stand. J. Clin. 
Lab. Invest. 24:145, 1969. 
91. Didisheim, P.: Inhibition by dipyridamole of 
arterial thrombosis in rats, Thromb. Diath. 
Haemorrh. 20:257, 1968, 
92. Sullivan, J. M., Kagnoff, M. F., and Gorlin, R.: 
Reduction of platelet adhesiveness in patients 
with coronary artery disease, Amer. J. Med. 
Sci. 255:292, 1968. 
93. Mayne, E. E., Bridges, J. M., and Weaver, 
J. A.: The effect of dipyridamole on increased 
levels of platelet adhesiveness, J. Atheroscler. 
Res. 9:335, 1969. 










Philp, R. B., and Lemieux, J. P. V.: Inter- 
actions of dipyridamole and adenosine on 
platelet aggregation, Nature 221:1162, 1969. 
Philp, R. B., and Lemieux, V.: Comparison of 
some effects of dipyridamole and adenosine on 
thrombus formation, platelet adhesiveness and 
blood pressure in rabbits and rats, Nature 
218:1072, 1968. 
Colman, R. W., Braun, W. E., Busch, G. J., 
Dammin. G. 1.. and Merrill. T. P.: Coagulation 
studies in the hyperacute and other forms of 
renal-allograft rejection, New England J. Med. 
281:685, 1969. 
Rosenberg, J, C., Broersma, J. C., Bullemer, 
G., Mammen, E. F., Lenaghan, R., and Rosen- 
berg, B. F.: Relationship of platelets, blood 
coagulation, and fibrinolysis to hyperacute 
rejection of renal xenografts, Transplantation 
8:152, 1969. 
Mowbray, J.: Platelet thrombi in rejection 
episodes, Proc. Roy. Sot. Med. 62:597, 1969. 
Duffy, J. L., Cinque, T., Grishman, E., and 
Churg, J.: Intraglomerular fibrin, platelet 
aggregation, and subendothelial deposits in 
lipoid nephrosis, J. Chin. Invest.. 49:251, 1970. 
Dempster, W. J.: Dipyridamole and rejection 
reactions, Lancet 2:1140, 1969. 
Kincaid-Smith, P.: Modification of the vascu- 
lar lesions of rejection in cadaveric renal allo- 
grafts by dipyridamole and anticoagulants. 
Lancet 2:920, 1969. 
